Nitric Oxide Synthase 3 Gene Variants and Colorectal Cancer: a Meta-Analysis

Yang, Chen; Li, Jie; Guo, Yun; Guo, Xiaoyun

doi:10.7314/apjcp.2014.15.8.3811

Cited by 5 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier, Hao et al (2010) reported significant association between NOS3 G894T polymorphism and breast cancer risk, but he included three ineligible studies, which was further corrected by the meta-analysis of Fu et al (2011), where they excluded those three ineligible studies and found no association between NOS3 G894T polymorphism and breast cancer risk (Hao et al, 2010;Fu et al, 2011). A recent meta-analysis about the rs1799983 and rs2070744 with 2,745 cases and 2,478 controls found no significant association for NOS3 G894T/rs1799983 with colorectal cancer risk (Chen et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

G894T and 4a/b Polymorphisms of NOS3 Gene are Not Associated with Cancer Risk: a Meta-analysis

Haque

Mandal²,

Akhter³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Endothelial nitric oxide synthase (eNOS or NOS3) produces nitric oxide and genetic polymorphisms of NOS3 gene play significant roles in various processes of carcinogenesis. The results from published studies on the association between NOS3 G894T and NOS3 intron 4 (4a/b) polymorphisms and cancer risk are conflicting and inconclusive. However, i n order to assess this relationship more precisely, a meta-analysis was performed with PubMed (Medline), EMBASE and Google web searches until February 2014 to select all published casecontrol and cohort studies. Genotype distribution data were collected to calculate the pooled odd ratios (ORs) and 95% confidence intervals (CIs) to evaluate the strength of association. A total of 10,546 cancer cases and 10,550 controls were included from twenty four case-control studies for the NOS3 G894T polymorphism. The results indicated no significant association with cancer risk as observed in allelic (T vs G: OR=1.024, 95%CI=0.954 to 1.099, p=0.508), homozygous (TT vs GG: OR=1.137, 95%CI=0.944 to 1.370, p=0.176), heterozygous (GT vs GG: OR=0.993, 95%CI=0.932 to 1.059, p=0.835), recessive (TT vs GG+GT: OR=1.100, 95%CI=0.936 to 1.293, p=0.249) and dominant (TT+GT vs GG: OR=1.012, 95%CI=0.927 to 1.105, p=0.789) genetic models. Similarly, a total of 3,449 cancer cases and 3,691 controls were recruited from fourteen case-control studies for NOS3 4a/b polymorphism. Pooled results indicated no significant association under allelic (A vs B: OR=0.981, 95%CI=0.725 to 1.329, p=0.902), homozygous (AA vs BB: OR=1.166, 95%CI=0.524 to 2.593, p=0.707), heterozygous (BA vs BB: OR=1.129, 95%CI=0.896 to 1.422, p=0.305), dominant (AA+BA vs BB: OR=1.046, 95%CI=0.779 to 1.405, p=0.763) and recessive (AA vs BB+BA: OR=1.196, 95%CI=0.587 to 2.439, p=0.622) genetic contrast models. This meta-analysis suggests that G894T and 4a/b polymorphisms of NOS3 gene are not associated with increased or decreased risk of overall cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

G894T and 4a/b Polymorphisms of NOS3 Gene are Not Associated with Cancer Risk: a Meta-analysis

Haque

Mandal²,

Akhter³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…18 The significance of this SNP has been reported in the development of acute toxicity in individuals suffering from breast cancer patients with radiotherapy treatment 21 and colorectal cancer. 22 Considering the role of Cav-1 in PC and its effect on the regulation of eNOS, we aimed to investigate the association of CAV1 T29107A and eNOS G894T polymorphisms with PC susceptibility in a population from west of Iran. Additionally, we assessed the effect of the above mentioned polymorphisms on serum concentration of testosterone, NO and PSA.…”

Section: Introductionmentioning

confidence: 99%

The role of caveolin‐1 and endothelial nitric oxide synthase polymorphisms in susceptibility to prostate cancer

Aliyari

Komi

Kiani

et al. 2021

Int J Experimental Path

View full text Add to dashboard Cite

Caveolin-1(cav-1) is overexpressed in prostate cancer (PC) and is associated with progression of the disease. We investigated the effects of CAV1-T29107A and endothelial nitric oxide synthase (eNOS) G894T polymorphisms on the serum levels of testosterone, NO and prostate-specific antigen (PSA) in patients with PC. We genotyped cav-1 and eNOS genes in 112 PC patients and 150 healthy controls by PCR-RFLP. Serum levels of NO − 2 and NO − 3 were measured using spectrophotometry, and serum levels of testosterone and PSA were measured by ELISA. The frequencies of CAV1 genotypes A/T vs. A/A according to the dominant model AT + TT vs.AA genotype and T allele were significantly higher in PC patients in comparison with the control group and considerably increased the risk of disease by 2.19-, 1.44and 1.6-fold, respectively. AT + TT genotypes were associated significantly with the increased risk of PC in those with smoking or diabetes by 3.08-fold (P = .004).Individuals carrying concurrently the T allele of CAV1 A29107T and the T allele of eNOS G894T genes had a significantly increased risk of PC by 2.52-fold (P = .009).We did not find any significant relationship between eNOS G894T genotypes and alleles with susceptibility to PC. Our results highlighted the significance of CAV1-T29107A SNP but not (eNOS) G894T in the susceptibility to PC in our the population that we have studied.

show abstract

“…Colorectal cancer has become the third reason of cancer death in China and its incidence is increasing year by year (Chen et al, 2014). Surgical treatment is the most effective and preferred method for most resectable colorectal cancer.…”

Section: Introductionmentioning

confidence: 99%

Seniors Have a Better Learning Curve for Laparoscopic Colorectal Cancer Resection

Zhang¹,

Wang²,

Liang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: This study was designed to evaluate the outcomes of laparoscopic colorectal resection in a period of learning curve completed by surgeons with different experience and aptitudes with a view to making clear whether seniors had a better learning curve compared with juniors. Methods: From May 2010 to August 2012, the first twenty patients underwent laparoscopic colorectal resection completed by each surgeon were selected for analysis retrospectively. A total of 240 patients treated by 5 seniors and 7 juniors were divided into the senior group (n=100) and the junior group (n=140). The short-term outcomes of laparoscopic surgery of the two groups were compared. Results: The mean numbers of lymph nodes harvested were 21.2±11.0 in the senior group and 17.3±11.5 in the junior group (p=0.010); The mean operative times were 187.9±60.0min as compared to 231.3±55.7 min (p=0.006), and blood loss values were 177.0±100.7ml and 234.0±185ml, respectively (p=0.001); Conversion rate in the senior group was obviously lower than in the junior group (10.0% vs 20.7%, p=0.027) and the mean time to passing of first flatus were 3.3±0.9 and 3.8±0.9 days (p=0.001). For low rectal cancer, the sphincter preserving rates were 68.7% and 35.3% (p=0.027). Conclusions: Seniors could perform laparoscopic colorectal resection with relatively better oncological outcomes and quicker recovery, and seniors could master the laparoscopic skill more easily and quickly. Seniors had a better learning curve for laparoscopic colorectal cancer resection compared to juniors.

show abstract

Nitric Oxide Synthase 3 Gene Variants and Colorectal Cancer: a Meta-Analysis

Cited by 5 publications

References 35 publications

G894T and 4a/b Polymorphisms of NOS3 Gene are Not Associated with Cancer Risk: a Meta-analysis

G894T and 4a/b Polymorphisms of NOS3 Gene are Not Associated with Cancer Risk: a Meta-analysis

The role of caveolin‐1 and endothelial nitric oxide synthase polymorphisms in susceptibility to prostate cancer

Seniors Have a Better Learning Curve for Laparoscopic Colorectal Cancer Resection

Contact Info

Product

Resources

About